



# Annual General Meeting of Shareholders

**Telix Pharmaceuticals (ASX:TLX)**

11.00am AEST

24 May 2023



# Important information

This presentation is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This presentation contains summary information about Telix Pharmaceuticals Limited (ACN 616 620 369) and its related bodies corporate (together, Telix) and Telix's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with Telix's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at [www.asx.com.au](http://www.asx.com.au). This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire Telix shares or other securities.

Telix products are currently investigational use only unless indicated and are subject to future regulatory developments and product approvals. Except for Illuccix® (Ga-68 gozetotide injection), none of the other products have received a marketing authorisation in any jurisdiction. Registrations vary country to country. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country-specific product information, package leaflets or instructions for use. Any content relating to third party products is based on publicly available data and is accurate at the date of presentation.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Telix or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of Telix or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to Telix, including statements regarding Telix's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to Telix's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project", "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on Telix's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect Telix's business and operations in the future. Telix does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties, and assumptions and other important factors, many of which are beyond the control of Telix, that could cause the actual results, performances or achievements of Telix to be materially different to future results, performances or achievements expressed or implied by the statements. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and Telix's ability to protect its patents and other intellectual property.

The audience should read this presentation together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, Telix does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Copyright and Trademarks

©2023 Telix Pharmaceuticals Limited. Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to Telix (all rights reserved).



# H Kevin McCann AO Chairman



# Board of Directors



**H Kevin McCann AO**

Non-Executive  
Director and  
Chairman



**Christian  
Behrenbruch**

Managing Director  
and Group CEO



**Andreas Kluge**

Non-Executive  
Director



**Mark Nelson**

Non-Executive  
Director



**Tiffany Olson**

Non-Executive  
Director



**Jann Skinner**

Non-Executive  
Director

Note: Dr Andreas Kluge is currently on a leave of absence from the Board of Directors, for a period of approximately six months.

# Meeting agenda

- 01**      **Chairman's address**
- 02**      **CEO's address**
- 03**      **Formal items of business,  
including voting and questions**



# Video

# Annual General Meeting of Shareholders

Chairman's address



H Kevin McCann AO



# Annual General Meeting of Shareholders

CEO's address

Dr Christian Behrenbruch



# Delivering to our growth strategy

## Our key accomplishments in 2022




### Commercialise the diagnostics portfolio

- \$247M revenue from Illuccix U.S., sales since launch in April 2022
- Illuccix label expansion
- EU / UK submissions filed
- ZIRCON Phase III readout
- Commercialising two additional products



### Unlock value in the therapeutic pipeline

- ProstACT SELECT study fully enrolled
- Manufacturing scale-up to support ProstACT GLOBAL
- First patients dosed in STARLITE-2 (TLX250)
- STARSTRUCK study ethics approval (TLX250 combo)
- IPAX-2 initiated based on positive results from IPAX-1



### Strengthen supply chain and manufacturing

- U.S. distribution network expanded to 202 radiopharmacies
- Buildout of Brussels South production facility
- Acquisition of Optimal Tracers
- Multiple clinical and commercial supply agreements



### Expand the pipeline

- Olaratumab (TLX300) in-licensed and demonstrated proof of concept
- Development of AI platform and acquisition of Dedicaid
- Multiple collaboration partnerships driving “future frontier” development

# Leadership in urologic oncology

Building deep relationships with the Illuccix customer

Supporting the urologic patient across the continuum of imaging, surgery and therapy




**Prostate cancer**



**Kidney cancer**



**Bladder cancer**



**Diagnosis and staging**

*Advanced imaging*

**Surgical technologies**

*Radio-guided surgery and  
biology-guided radiation*

**Therapy**


*Targeted radiation as therapy  
Imaging to monitor response to therapy*

**Artificial Intelligence platform:** Reader and clinical decision support > automation, longitudinal data, disease prediction


# Transition to a financially sustainable company

## Continual improvement across key financial metrics

### Adjusted EBITDAR (\$M)




### Key expenditure (\$M) and percentage of sales



# Developing a world-class organisation

We have effectively scaled to optimise development and drive commercial success



# Four major focus areas for 2023

Value creating catalysts across the imaging and therapeutic pipeline

**Illuccix® -  
continued revenue  
growth and global  
rollout**

**ProstACT  
GLOBAL patient  
recruitment and  
ProstACT  
SELECT/TARGET  
data readouts**

**New Drug  
Application (NDA)  
for brain cancer  
imaging  
(TLX101-CDx)**

**Biologics License  
Application (BLA)  
submission for  
TLX250-CDx**

# Investor contact

Kyahn Williamson

SVP Investor Relations and  
Corporate Communication

[kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)



*Authorised for release to the ASX by the Telix Board of Directors*